P/E Ratio

The P/E ratio (price-to-earnings ratio) compares a stock’s price to its per-share earnings; at 39.0x, investors are paying $39 for every $1 of BDX’s annual earnings, indicating a premium valuation.

This is well above the healthcare sector median of 28.3x, placing BDX in the 75th percentile among peers—meaning it trades at a higher multiple than 75% of comparable companies. Over the last eight quarters, the P/E has increased from 25.2x to 39.0x, though the year-over-year and quarter-over-quarter changes are both exactly +0.0%, showing no recent movement. A high, flat P/E in an increasing trend suggests that the stock’s earnings have not grown to justify the elevated multiple, creating downside risk if earnings expectations are not met. This combination of a lofty valuation and stagnant earnings momentum implies a cautious stance for investors seeking margin of safety. The metric contradicts the NEUTRAL verdict because a high P/E relative to sector peers and a history of sustained expansion typically warrants a more bearish assessment, not a neutral one.

Frequently Asked Questions

Closest Sector Peers